William Rice
Chief Executive Officer bei APTOSE BIOSCIENCES INC.
Vermögen: 56 799 $ am 31.03.2024
Profil
William G.
Rice is the founder of Achillion Pharmaceuticals, Inc., which was founded in 1998.
He held the title of President, Chief Executive Officer & Director from 1998 to 2003.
Dr. Rice's current job(s) include being the Chairman, President, CEO & CAO at Aptose Biosciences, Inc. since 2013 and the Chairman at Cylene Pharmaceuticals, Inc. since 2003.
His former job(s) include serving as an Independent Director at Oncolytics Biotech, Inc. from 2015 to 2021, being a Member-Pediatric Hematology & Oncology at Emory University School of Medicine from 1989 to 1992, and working as a Senior Scientist & Head-Drug Mechanism Lab at Frederick National Laboratory For Cancer Research from 1992 to 1998.
Dr. Rice obtained his doctorate degree from Emory University in 1986.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0,22% | 05.02.2024 | 34 216 ( 0,22% ) | 56 799 $ | 31.03.2024 |
Aktive Positionen von William Rice
| Unternehmen | Position | Beginn |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Chief Executive Officer | 28.10.2013 |
Cylene Pharmaceuticals, Inc.
 Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Chairman | 28.09.2010 |
Ehemalige bekannte Positionen von William Rice
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Director/Board Member | 01.01.2021 |
| ACHILLION PHARMACEUTICALS, INC. | Founder | 01.08.2003 |
| Frederick National Laboratory For Cancer Research | Corporate Officer/Principal | 01.01.1998 |
| Emory University School of Medicine | Corporate Officer/Principal | 01.01.1992 |
Ausbildung von William Rice
| Emory University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
| Frederick National Laboratory For Cancer Research |
